The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic. OBJECTIVE: Determine the rate of TB infection after a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Abdullah Al-Sohaim, Abdullah Saleh Bawazir, Turki Al-Turki, Eiman Omar Alsafi, Abdullah Al-Roqy, Layla Layqah, Salim Alawi Baharoone
Formato: article
Lenguaje:EN
Publicado: King Faisal Specialist Hospital and Research Centre 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/509a4578978a4742b75b0e1ee2ff05a3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares